Evangelos Digkas

Eskilstuna, D 63349, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

A mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practice.

A mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practice.

Journal: BMC health services research

Published: March 18, 2026

Influenza Vaccination Among Patients With Cancer Treated With Checkpoint Inhibitors: Association With Survival Outcomes and Immune-Related Adverse Events.

Influenza Vaccination Among Patients With Cancer Treated With Checkpoint Inhibitors: Association With Survival Outcomes and Immune-Related Adverse Events.

Journal: JCO oncology practice

Published: February 09, 2026

Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study.

Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study.

Journal: BMC cancer

Published: January 27, 2026

CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study.

CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study.

Journal: Journal of geriatric oncology

Published: November 25, 2025

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting.

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting.

Journal: Breast (Edinburgh, Scotland)

Published: October 29, 2024

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: August 28, 2024

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness.

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness.

Journal: Frontiers in oncology

Published: March 11, 2024

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis.

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis.

Journal: Pigment cell & melanoma research

Published: September 13, 2023

Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study.

Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study.

Journal: Breast cancer research and treatment

Published: June 30, 2023

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.

Journal: Cancer medicine

Published: February 02, 2023

Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis.

Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis.

Journal: Targeted oncology

Published: July 11, 2022

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.

Journal: EJHaem

Published: March 16, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026